Founded in 1982 and based in France, BYG4lab (the “Company”) develops software solutions designed to enhance laboratory performance, offering a number of key advantages: streamlined workflow management, more efficient instrument integration, configuration management for mega-laboratories, custom dashboard design, maximized automated validation, and quality control management. The Company serves both centralized and decentralized laboratories, across all areas of clinical biology—including immunochemistry, hematology, molecular biology, microbiology, and more—and supports over 4,500 individual laboratories, including some of Europe’s leading players.
BYG4lab is a key European leader and offers one of the most comprehensive solutions on the market. The Company provides tools for all laboratory activity segments, and enables connectivity with all types of diagnostic devices. BYG4lab’s services cover the entire software lifecycle, from license sales and installation to maintenance and after-sales support. Its products deliver best-in-class technological capabilities, including an outstanding user experience, made possible by significant investments in R&D.
Since its acquisition by Cyril Verhille in 2012, with the financial support of IRDI Capital Investissement, the Company has experienced significant growth. Today, BYG4lab employs nearly 100 people, with approximately 40% dedicated to R&D, and achieves double-digit annual sales growth. The Company enjoys a strong reputation among its clients, thanks in particular to its ability to deliver turnkey solutions, meet customer needs by enhancing operational efficiency, deliver high-quality results, and improve profitability.
The Company benefits from a proven business model in an attractive and continuously growing market. Keensight Capital will support BYG4lab’s management team in its ambition to become the global leader in laboratory data management software, by expanding into new strategic regions in Europe and North America, targeting additional industry sectors, and further diversifying its product portfolio and partner network through the development of new products and strategic alliances. These value creation drivers will be pursued through both organic growth and acquisitions.
The Line Avocats advises IRDI Capital Investissement on this new transaction carried out alongside Keensight Capital.
Learn more:
